|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lepor H: Surgical treatment of prostate
carcinoma. J Urol 197 (2S). S41–S42. 2017.
|
|
3
|
Gundem G, Van Loo P, Kremeyer B,
Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML,
Högnäs G, Annala M, et al: The evolutionary history of lethal
metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan W, Li H, Zhou Y, Huang Z, Rong S, Xia
M, Ji Z, Chen J and Jiang Y: Prostate carcinoma spatial
distribution patterns in Chinese men investigated with systematic
transperineal ultrasound guided 11-region biopsy. Urol Oncol.
27:520–524. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lian J, Wu X, He F, Karnak D, Tang W, Meng
Y, Xiang D, Ji M, Lawrence TS and Xu L: A natural BH3 mimetic
induces autophagy in apoptosis-resistant prostate cancer via
modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell
Death Differ. 18:60–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Effert P, Beniers AJ, Tamimi Y, Handt S
and Jakse G: Expression of glucose transporter 1 (Glut-1) in cell
lines and clinical specimens from human prostate adenocarcinoma.
Anticancer Res. 24:3057–3063. 2004.PubMed/NCBI
|
|
7
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmidt LH, Görlich D, Spieker T, Rohde C,
Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Huge A, et
al: Prognostic impact of Bcl-2 depends on tumor histology and
expression of MALAT-1 lncRNA in non-small-cell lung cancer. J
Thorac Oncol. 9:1294–1304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X and Gan B: lncRNA NBR2 modulates
cancer cell sensitivity to phenformin through GLUT1. Cell Cycle.
15:3471–3481. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gasri-Plotnitsky L, Ovadia A, Shamalov K,
Nizri-Megnaji T, Meir S, Zurer I, Cohen CJ and Ginsberg D: A novel
lncRNA, GASL1, inhibits cell proliferation and restricts E2F1
activity. Oncotarget. 8:23775–23786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Malik SS, Kazmi Z, Fatima I, Shabbir R,
Perveen S and Masood N: Genetic polymorphism of GSTM1 and GSTT1 and
risk of prostatic carcinoma-a meta-analysis of 7,281 prostate
cancer cases and 9,082 healthy controls. Asian Pac J Cancer Prev.
17:2629–2635. 2016.PubMed/NCBI
|
|
12
|
Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST,
Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB and Xu J: Human
polymorphisms at long non-coding RNAs (lncRNAs) and association
with prostate cancer risk. Carcinogenesis. 32:1655–1659. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou W, Wang Z, Tao Z, Ji L, Zhou B, Shen
M and Tu H: Differential expression of long non-coding RNAs in
prostatic carcinoma cell line LNCaP after occurrence of androgen
independent transformation. Int J Clin Exp Pathol. 10:6665–6673.
2017.
|
|
14
|
Hori SS and Gambhir SS: Mathematical model
identifies blood biomarker-based early cancer detection strategies
and limitations. Sci Transl Med. 3:109ra1162011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grammatikakis I, Panda AC, Abdelmohsen K
and Gorospe M: Long noncoding RNAs(lncRNAs) and the molecular
hallmarks of aging. Aging (Albany NY). 6:992–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayfield RD: Emerging roles for ncRNAs in
alcohol use disorders. Alcohol. 60:31–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Qiu M, Xu Y, Li M, Dong G, Mao Q,
Yin R and Xu L: Long noncoding RNA CCAT2 correlates with smoking in
esophageal squamous cell carcinoma. Tumour Biol. 36:5523–5528.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Li X, Bai M, Suo Y, Zhang G and Cao
X: Matrine inhibited proliferation and increased apoptosis in human
breast cancer MCF-7 cells via upregulation of Bax and
downregulation of Bcl-2. Int J Clin Exp Pathol. 8:14793–14799.
2015.PubMed/NCBI
|
|
19
|
Kurahara H, Maemura K, Mataki Y, Sakoda M,
Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, et al:
Significance of glucose transporter type 1 (GLUT-1) expression in
the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann
Surg Oncol. 25:1432–1439. 2018. View Article : Google Scholar : PubMed/NCBI
|
